Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Neogenomics (NEO) Acquisitions (2020 - 2025)

Neogenomics filings provide 4 years of Acquisitions readings, the most recent being $463000.0 for Q3 2025.

On a quarterly basis, Acquisitions changed N/A to $463000.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $463000.0, a N/A change, with the full-year FY2025 number at $6.5 million, changed N/A from a year prior.
Acquisitions hit $463000.0 in Q3 2025 for Neogenomics, down from $419.4 million in the prior quarter.
In the past five years, Acquisitions ranged from a high of $419.4 million in Q2 2021 to a low of $463000.0 in Q3 2025.